Takeshi Goda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Takeshi Goda has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hisakazu Nakajima
Department of Pediatrics , 12898 Kyoto Prefectural University of Medicine , Kyoto , Japan
2 shared publications Chiharu Cho
Department of Pediatrics, Graduate School of Medical Science Kyoto Prefectural University of Medicine Japan
1 shared publication- Hiroshi Komatsu
Department of Pediatrics, National Hospital Organization Maizuru Medical Center, Kyoto, Japan
1 shared publication - Kandai Nozu
Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
1 shared publication Madoka Konishi
Department of Pediatrics, Graduate School of Medical Science Kyoto Prefectural University of Medicine Japan
1 shared publicationMasahide Hamaguchi
Department of Endocrinology and Metabolism, Graduate School of Medical Science Kyoto Prefectural University of Medicine Japan
1 shared publication
Latest Publications
- Open Access
- 31 January 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (7) , 1328-1339
Erythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice
Obesity‐related liver disease remains a critical global health challenge, underscoring the need to elucidate the molecular mechanisms underlying hepatic inflammation and metabolic dysfunction, and to identify novel therapeutic targets. This study aimed to determine whether erythropoietin (EPO) modulates soluble epoxide hydrolase (sEH) and lipid mediator pathways to ameliorate hepatic inflammation and metabolic dysfunction in high‐fat diet (HFD)‐induced obese mice. Male C57BL/6 mice were fed HFD with or without EPO treatment, and metabolic phenotyping, including glucose tolerance testing and homeostasis model assessment of insulin resistance, was performed. Hepatic histology and quantitative real‐time polymerase chain reaction were conducted, together with flow cytometry to assess macrophage polarization, western blotting for sEH, and targeted liquid chromatography–tandem mass spectrometry profiling of cytochrome P450 epoxygenase‐derived epoxides. EPO treatment improved glucose metabolism, reduced hepatic steatosis, lowered Ccr2 , Mcp1 , and Tnfα expression, promoted a shift of hepatic macrophages toward an M2 (anti‐inflammatory) phenotype, downregulated hepatic sEH protein levels, and increased both hepatic and plasma concentrations of epoxygenase‐derived epoxides. These findings indicate that EPO suppresses hepatic sEH and favors pro‐resolving lipid mediator signaling, suggesting a potential therapeutic avenue for obesity‐related hepatic inflammation.
- 31 January 2026
- Published by Wiley in FEBS Open Bio
- Vol. 16 (7) , 1328-1339
Open AccessErythropoietin modulates hepatic inflammation, glucose homeostasis, and soluble epoxide hydrolase and epoxides in high‐fat diet‐induced obese mice
Obesity‐related liver disease remains a critical global health challenge, underscoring the need to elucidate the molecular mechanisms underlying hepatic inflammation and metabolic dysfunction, and to identify novel therapeutic targets. This study aimed to determine whether erythropoietin (EPO) modulates soluble epoxide hydrolase (sEH) and lipid mediator pathways to ameliorate hepatic inflammation and metabolic dysfunction in high‐fat diet (HFD)‐induced obese mice. Male C57BL/6 mice were fed HFD with or without EPO treatment, and metabolic phenotyping, including glucose tolerance testing and homeostasis model assessment of insulin resistance, was performed. Hepatic histology and quantitative real‐time polymerase chain reaction were conducted, together with flow cytometry to assess macrophage polarization, western blotting for sEH, and targeted liquid chromatography–tandem mass spectrometry profiling of cytochrome P450 epoxygenase‐derived epoxides. EPO treatment improved glucose metabolism, reduced hepatic steatosis, lowered Ccr2 , Mcp1 , and Tnfα expression, promoted a shift of hepatic macrophages toward an M2 (anti‐inflammatory) phenotype, downregulated hepatic sEH protein levels, and increased both hepatic and plasma concentrations of epoxygenase‐derived epoxides. These findings indicate that EPO suppresses hepatic sEH and favors pro‐resolving lipid mediator signaling, suggesting a potential therapeutic avenue for obesity‐related hepatic inflammation.
- Open Access
- 1 January 2020
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 29 (3) , 127-130
An infantile case of pseudohypoaldosteronism type 1 (PHA1) caused by a novel mutation of NR3C2
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2020
- Published by Japanese Society for Pediatric Endocrinology in Clinical Pediatric Endocrinology
- Vol. 29 (3) , 127-130
Open AccessAn infantile case of pseudohypoaldosteronism type 1 (PHA1) caused by a novel mutation of NR3C2
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies